Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals, Inc. (MDGL) is a healthcare company (biotechnology) based in the United States. The share price is $426.40, up 0.58% on the day, which values the company at $9.91B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.

Key facts

Share price
$426.40+0.58% today
Market value
$9.91B
Forward P/E
41.1×
200-week average
$335.2727% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Madrigal Pharmaceuticals, Inc. in more detail

MDGL trades at 41.1× next year's expected earnings, 6.9× sales. It sits 27% above its 200-week average of $335.27.

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Beneish M-score flags the accounts; Weak Piotroski score.

5 of the superinvestors tracked here hold MDGL, including John Paulson (27.9% of the portfolio), Julian and Felix Baker (5.8% of the portfolio), Brandon Haley (0.2% of the portfolio).

Superinvestors holding MDGL

5 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:MDGL vs GMED (Madrigal Pharmaceuticals, Inc. vs Globus Medical)MDGL vs BRKR (Madrigal Pharmaceuticals, Inc. vs Bruker)MDGL vs HSIC (Madrigal Pharmaceuticals, Inc. vs Henry Schein)MDGL vs PODD (Madrigal Pharmaceuticals, Inc. vs Insulet)MDGL vs QGEN (Madrigal Pharmaceuticals, Inc. vs Qiagen)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Madrigal Pharmaceuticals, Inc. (MDGL): questions and answers

What is Madrigal Pharmaceuticals, Inc.'s market cap?

Madrigal Pharmaceuticals, Inc. is valued at $9.91B at a share price of $426.40.

Is MDGL above its 200-week moving average?

Yes. MDGL is 27.2% above its 200-week average of $335.27. Long-term investors watch that line because strong companies rarely trade below it for long.

Does MDGL pay a dividend?

Madrigal Pharmaceuticals, Inc. does not currently pay a regular dividend.

Which famous investors own MDGL?

In their latest quarterly filings, John Paulson (27.9% of the portfolio), Julian and Felix Baker (5.8% of the portfolio), Brandon Haley (0.2% of the portfolio), Takis Sparaggis (0.2% of the portfolio), Ken Griffin (0.2% of the portfolio) hold MDGL. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Madrigal Pharmaceuticals, Inc. (MDGL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MDGL

Underlying data: Yahoo Finance; company filings with the SEC.